Rodman & Renshaw initiated coverage of Kyverna Therapeutics with a Buy rating and $16 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna treatment of systemic sclerosis granted FDA orphan designation
- Kyverna announces presentation on KYV-101 at ECTRIMS
- Kyverna Therapeutics Announces Executive Leadership Changes
- Kyverna Therapeutics names Warner Biddle as CEO, succeeding Peter Maag
- Kyverna Therapeutics treatment of stiff person syndrome gets orphan designation